Latest Videos

Technical and Diagnostic Limitations to Partial Prostate Ablation for Prostate Cancer

Technical and Diagnostic Limitations to Partial Prostate Ablation for Prostate Cancer

Posted by | Apr 2020

Michael O. Koch, MD, provides an overview of High Intensity Focused Ultrasound (HIFU) and Transurethral Ultrasound Ablation (TULSA-PRO), focal prostate ablation therapies that have recently shown promise as treatments for localized prostate cancer. Both treatments only have de novo approval from the FDA and have no specific indication for prostate cancer and there have been some disappointing international studies of the therapies. However, several studies with carefully-selected patients who are not thriving on active surveillance, have unilateral significant disease, and have limited calcifications have had remarkable results, with high rates of failure-free survival and PSA reduction. For approximately 10-15% of prostate cancer patients, prostate ablation may be a very good technique.

Read More
Mitomycin Gel (UGN-101) Approved for Treating Low-Grade Upper Tract Urothelial Carcinoma: The OLYMPUS Trial

Mitomycin Gel (UGN-101) Approved for Treating Low-Grade Upper Tract Urothelial Carcinoma: The OLYMPUS Trial

Posted by | Apr 2020

Surena F. Matin, MD, Professor in the Department of Urology at MD Anderson Cancer Center in Houston, Texas, discusses the OLYMPUS Trial which studied the effects of mitomycin gel (UGN-101) in treating low-grade upper tract urothelial carcinoma. The FDA has recently approved this drug for treatment after the trial’s successful results. Prior to approval, there was no method of treatment that allowed for topical therapies in upper-tract cancer cases like there is for the bladder, and there had been little research into potential treatments. Dr. Matin was an investigator on the trial and discusses the selection of participants, the procedures of the trial, and the conclusions that were drawn. He highlights that during the trial, 58% of participants had a complete response, and that fully optimizing the drug plays an important role in those high numbers of success. He also discusses some of the adverse events that occurred during the trial and considerations for using mitomycin gel as a treatment.

Read More
Advanced Prostate Cancer: What’s Changing

Advanced Prostate Cancer: What’s Changing

Posted by | Apr 2020

Richard G. Harris, MD, President of LUGPA and UroPartners, discusses the recent incorporation of advanced prostate cancer (APC) clinics amongst LUGPAs within the United States. He goes on to discuss why APC clinics are important, clinical trials for m0, m1, and castrate sensitive prostate cancer, as well as the importance of genetic testing within an APC clinic.

Read More
Telemedicine Etiquette for Urologists

Telemedicine Etiquette for Urologists

Posted by | Apr 2020

Neil H. Baum, MD, Clinical Professor of Urology at Tulane Medical School and author of the book Marketing Your Clinical Practice – Ethically, Effectively, and Economically, discusses why telemedicine etiquette is so important in these times of COVID-19. He emphasizes that good urologic care no longer requires doctors to touch the patients and that there are a large number of urologic patients that are very amenable to telemedicine. Dr. Baum highlights that many post-operative visits can be done via telemedicine, in some cases up to 50%, but emphasizes that successful meetings require preparation. He outlines the importance of having good equipment, lighting, and connectivity, as well as minimizing noise and other distractions. Dr. Baum also discusses some of the different tests that can be sent to a patient and be done from their home and the fact that more and more of this sort of patient care is going to become available as time goes on.

Read More